ASCO 2016

Social media speeds study recruitment for cancer researchers

By Melissa Fassbender contact

- Last updated on GMT

The researchers hope to engage with patients, regardless of where they, live via social media. (Image: iStock/cyther5)
The researchers hope to engage with patients, regardless of where they, live via social media. (Image: iStock/cyther5)

Related tags: Metastatic breast cancer, Cancer

Researchers used pre-existing platforms to identify and recruit patients for a cancer research study – connecting advocacy groups, social media, and a dedicated website to register patients.

According to the researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, the crowd-sourcing strategy was aimed at accelerating research into metastatic breast cancer – and was able to successfully register more than 2,000 patients from every US state in the first seven months.

The undertaking, The Metastatic Breast Cancer Project (MBC Project), collected health records, tumor specimens, and saliva samples to provide researchers with an understanding of how tumors metastasize, at a genomic level.

"It's really fast​," said Nikhil Wagle, MD, of the project. "The patients have already done much of the work, and they are excited to say 'count me in' and become partners with whom we can continuously provide feedback about our progress​."

Corrie Painter, PhD, and associate director for the project, added "We have leveraged what already exists in online communities as breast cancer support groups​.”

The project’s website specifically displays a “Count Me In” button that begins a patient’s enrollment process, after which they are asked about their cancer and treatments and are able to give researchers consent to access their medical records. Additionally, patients can opt in to receive a mailed collection kit to provide saliva samples, which are analyzed at the Broad Institute.

"With this approach, we hope to empower patients to directly participate in research, regardless of where they live, and contribute to the effort to improve outcomes for all people with advanced breast cancer​," said Wagle.

And the approach has worked – currently, 95% of the 2,000-plus registered patients have provided information, and more than 1,100 have consented to have their medical records accessed and to have next-generation sequencing performed on their tumor and saliva samples.

In the future, the researchers plan on using a “liquid biopsy” test to collect tumor DNA that is shed by cancer into the blood stream. With this technique, tumor DNA could be analyzed over a period of time to give researchers insight into how a patient’s cancer evolves and develops resistance.

The researchers presented these findings at The American Society of Clinical Oncology's (ASCO) Annual Meeting which is being held June 3 to 7 in Chicago, IL. Additional data will be shared by Broad Institute and Dana Farber via a data-sharing platform that is currently under development.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars